Institution
Sapienza University of Rome
Education•Rome, Lazio, Italy•
About: Sapienza University of Rome is a education organization based out in Rome, Lazio, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 62002 authors who have published 155468 publications receiving 4397244 citations. The organization is also known as: La Sapienza & Università La Sapienza di Roma.
Topics: Population, Medicine, Context (language use), Cancer, Nonlinear system
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A systematic review and meta‐analysis of placebo‐controlled studies published in the past 30 years to clarify whether sexual function would benefit from testosterone treatment in men with partially or severely reduced serum T levels.
Abstract: Summary Objectives The role of androgen decline in the sexual activity of adult males is controversial. To clarify whether sexual function would benefit from testosterone (T) treatment in men with partially or severely reduced serum T levels, we conducted a systematic review and meta-analysis of placebo-controlled studies published in the past 30 years. The aim of this study was to assess and compare the effects of T on the different domains of sexual life. Data source A comprehensive search of all published randomized clinical trials was performed in MEDLINE, the Cochrane Library, EMBASE and Current Contents databases. Review methods Guided by prespecified criteria, software-assisted data abstraction and quality assessed by two independent reviewers, a total of 17 randomized placebo-controlled trials were found to be eligible. For each domain of sexual function we calculated the standardized mean difference relative to T and reported the results of pooled estimates of T treatment using the random effect model of meta-analysis. Heterogeneity, reproducibility and consistency of the findings across studies were explored using sensitivity and metaregression analysis. Results Overall, 656 subjects were evaluated: 284 were randomized to T, 284 to placebo (P) and 88 treated in cross-over. The median study length was 3 months (range 1‐36 months). Our meta-analysis showed that in men with an average T level at baseline below 12 nmol/l, T treatment moderately improved the number of nocturnal erections, sexual thoughts and motivation, number of successful intercourses, scores of erectile function and overall sexual satisfaction, whereas T had no effect on erectile function in eugonadal men compared to placebo. Heterogeneity was explored by grouping studies according to the characteristics of the study population. A cut-off value of 10 nmol / l for the mean T of the study population failed to predict the effect of treatment, whereas the presence of risk factors for vasculogenic erectile dysfunction (ED), comorbidities and shorter evaluation periods were associated with greater treatment effects in the studies performed in hypogonadal, but not in eugonadal, men. Meta-regression analysis showed that the effects of T on erectile function, but not libido, were inversely related to the mean baseline T concentration. The meta-analysis of available studies indicates that T treatment might be useful for improving vasculogenic ED in selected subjects with low or low-normal T levels. The evidence for a beneficial effect of T treatment on erectile function should be tempered with the caveats that the effect tends to decline over time, is progressively smaller with increasing baseline T levels, and long-term safety data are not available. The present meta-analysis highlights the need, and pitfalls, for large-scale, long-term, randomized controlled trials to formally investigate the efficacy of T replacement in symptomatic middle-aged and elderly men with reduced T levels and ED.
457 citations
••
TL;DR: It is shown that both the ASDF- and the AMDF-based estimators outperform the direct cross-correlation based estimator for medium-high signal-to-noise ratios.
Abstract: Basic aspects of time delay estimation (TDE) based on sampled signals are investigated. The direct cross-correlation method is analyzed and compared to the average square difference function (ASDF) and the (addition only based) average magnitude difference function (AMDF) estimators, Their relative accuracy is theoretically evaluated, and previous empirical results are explained. It is shown that both the ASDF- and the AMDF-based estimators outperform the direct cross-correlation based estimator for medium-high signal-to-noise ratios. Moreover, the AMDF-based estimator, which avoids any multiplications, significantly reduces the computational complexity of the estimation procedure while offering only a moderate performance loss with respect to the ASDF based estimator. >
455 citations
••
TL;DR: In this paper, the authors reported the observation of a state consistent with X(3872) decaying into J/ψπ+π-decomposition, where the observed width was consistent with the detector resolution and the results were found to be converging well with the measurements by the Belle Collaboration using b± decays.
Abstract: The observation of a state consistent with X(3872) decaying into J/ψπ+π- was reported. The X(3872) mass was measured to be 3871.3±0.7(stat)±0.4(syst)MeV/c2 from a sample of 730±90 candidates. The observed width was consistent with the detector resolution. The results were found to be converging well with the measurements by the Belle Collaboration using b± decays.
455 citations
•
Istituto Superiore di Sanità1, United States Department of Energy2, Lawrence Berkeley National Laboratory3, New York University4, Casa Sollievo della Sofferenza5, Sapienza University of Rome6, Icahn School of Medicine at Mount Sinai7, Catholic University of the Sacred Heart8, Royal Children's Hospital9
TL;DR: It is reported that 22 of 129 individuals with Noonan syndrome without PTPN11 or KRAS mutation have missense mutations in SOS1, which encodes a RAS-specific guanine nucleotide exchange factor, and this finding defines a new mechanism by which upregulation of the RAS pathway can profoundly change human development.
Abstract: Noonan syndrome (NS) is a developmental disorder characterized by short stature, facial dysmorphia, congenital heart defects and skeletal anomalies1. Increased RAS-mitogenactivated protein kinase (MAPK) signaling due to PTPN11 and KRAS mutations cause 50 percent of NS2-6. Here, we report that 22 of 129 NS patients without PTPN11 or KRAS mutation (17 percent) have missense mutations in SOS1, which encodes a RAS-specific guanine nucleotide exchange factor (GEF). SOS1 mutations cluster at residues implicated in the maintenance of SOS1 in its autoinhibited form and ectopic expression of two NS-associated mutants induced enhanced RAS activation. The phenotype associated with SOS1 defects is distinctive, although within NS spectrum, with a high prevalence of ectodermal abnormalities but generally normal development and linear growth. Our findings implicate for the first time gain-of-function mutations in a RAS GEF in inherited disease and define a new mechanism by which upregulation of the RAS pathway can profoundly change human development.
455 citations
••
TL;DR: The ARMYDA-ACS trial indicates that even short-term pretreatment with atorvastatin may improve outcomes in patients with ACS undergoing early invasive strategy, and may support routine use of high-dose statins before intervention in Patients with ACS.
454 citations
Authors
Showing all 62745 results
Name | H-index | Papers | Citations |
---|---|---|---|
Charles A. Dinarello | 190 | 1058 | 139668 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Peter A. R. Ade | 162 | 1387 | 138051 |
H. Eugene Stanley | 154 | 1190 | 122321 |
Suvadeep Bose | 154 | 960 | 129071 |
P. de Bernardis | 152 | 680 | 117804 |
Bart Staels | 152 | 824 | 86638 |
Alessandro Melchiorri | 151 | 674 | 116384 |
Andrew H. Jaffe | 149 | 518 | 110033 |
F. Piacentini | 149 | 531 | 108493 |
Subir Sarkar | 149 | 1542 | 144614 |
Albert Bandura | 148 | 255 | 276143 |
Carlo Rovelli | 146 | 1502 | 103550 |
Robert C. Gallo | 145 | 825 | 68212 |
R. Kowalewski | 143 | 1815 | 135517 |